Skip to main content
editorial
. 2019 May 9;4(2):e000480. doi: 10.1136/esmoopen-2018-000480

Table 1.

Efficacy of PARPi according to HRD status in ovarian cancer

Clinical trial Drug Study population HRD role
ARIEL-212 Rucaparib, monotherapy Relapsed, platinum-sensitive ovarian cancer Higher efficacy in gBRCA1/2-mutated and/or LOH-high compared with LOH-low tumours. Not powered to show a difference between LOH-high and LOH-low tumours
ARIEL-320 Rucaparib, maintenance therapy Relapsed, platinum-sensitive ovarian cancer Efficacy regardless of LOH-status. Magnitude of the benefit dependent on LOH
NOVA-trial11 Niraparib, maintenance therapy Relapsed, platinum-sensitive ovarian cancer Efficacy regardless of HRD-status. Magnitude of the benefit dependent on HRD

HRD, homologous recombination repair deficiency; LOH, loss of heterozygosity; PARPi, PARP inhibitors.